Related Experiment Video
Updated: Dec 7, 2025
10:33
Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
Published on: October 15, 2018
8.5K
DNA methyltransferases in hematological malignancies.
Nguyet-Minh Hoang1, Lixin Rui1
1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53792, USA; Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53792, USA.
Journal of Genetics and Genomics = Yi Chuan Xue Bao
|September 30, 2020
Summary
DNA methyltransferases (DNMTs) regulate DNA methylation, crucial for blood cell development. Aberrant DNMT activity and mutations drive hematological malignancies like leukemia and lymphoma, making them therapeutic targets.
Area of Science:
- Epigenetics and Molecular Biology
- Hematology and Oncology
Background:
- DNA methyltransferases (DNMTs) are key enzymes regulating DNA methylation patterns.
- DNMT1, DNMT3A, and DNMT3B are mammalian DNMTs with distinct roles in methylation establishment and maintenance.
- Proper DNA methylation is essential for normal hematopoiesis and lymphocyte development.
Purpose of the Study:
- To review DNMT mechanisms and their role in hematopoiesis and lymphocyte differentiation.
- To discuss DNA methylation heterogeneity, DNMT mutations, and their pathogenic roles in leukemia and lymphoma.
- To highlight DNMT inhibitors as potential treatments for hematological malignancies.
Main Methods:
- Literature review of DNMT function, DNA methylation in hematological malignancies, and clinical studies.
- Analysis of DNMT mechanisms, mutations, and interactions with transcription factors.
- Summary of current therapeutic strategies involving DNMT inhibitors.
Main Results:
- DNMT dysregulation and mutations are critical molecular events in hematological malignancies.
- Aberrant DNA methylation contributes to the pathogenesis of leukemia and lymphoma.
- DNMT inhibitors show promise in treating these cancers by targeting aberrant methylation.
Conclusions:
- Understanding DNMTs' roles in DNA methylation is vital for comprehending hematological malignancies.
- Targeting DNMTs offers a promising therapeutic avenue for leukemia and lymphoma.
- Further research into DNA methylation targets and DNMT inhibitor efficacy is warranted.
